Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine



   hyperuricemia
  

Disease ID 750
Disease hyperuricemia
Definition
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
Synonym
high blood uric acid level
hyperuricaemia
hyperuricaemia (disorder)
hyperuricaemia [ambiguous]
hyperuricaemic
hyperuricemia (disorder)
hyperuricemia [disease/finding]
hyperuricemia, nos
uric acid elevated
uric acid retention
uricacidaemia
uricacidemia
uricacidemia, nos
DOID
UMLS
C0740394
MeSH
SNOMED-CT
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:63)
C0020538  |  hypertension  |  37
C0018099  |  gout  |  33
C0948265  |  metabolic syndrome  |  20
C0022658  |  kidney disease  |  18
C0022661  |  chronic kidney disease  |  14
C0011847  |  diabetes  |  14
C0042373  |  vascular disease  |  11
C0028754  |  obesity  |  10
C0007222  |  cardiovascular disease  |  9
C0022658  |  renal disease  |  6
C0011849  |  diabetes mellitus  |  6
C1561644  |  chronic kidney disease (ckd)  |  6
C0018801  |  heart failure  |  5
C0004153  |  atherosclerosis  |  4
C0007222  |  cardiovascular diseases  |  3
C0022658  |  nephropathy  |  3
C0018799  |  heart disease  |  3
C0011860  |  type 2 diabetes  |  3
C0003864  |  arthritis  |  3
C0035078  |  renal failure  |  3
C0020459  |  hyperinsulinemia  |  3
C0010068  |  coronary artery disease  |  3
C0042373  |  vascular diseases  |  3
C0011860  |  type 2 diabetes mellitus  |  2
C1565489  |  renal insufficiency  |  2
C0010674  |  cystic fibrosis  |  2
C0019061  |  hemolytic uremic syndrome  |  2
C0085580  |  essential hypertension  |  2
C0022658  |  renal diseases  |  2
C0033687  |  proteinuria  |  2
C0024299  |  lymphoma  |  2
C0032914  |  preeclampsia  |  2
C0013537  |  eclampsia  |  2
C0152021  |  congenital heart disease  |  1
C0022408  |  joint disease  |  1
C0042075  |  urological diseases  |  1
C0027708  |  wilms tumor  |  1
C0027765  |  neurological disease  |  1
C0403447  |  chronic renal insufficiency  |  1
C0037315  |  sleep apnea  |  1
C0036421  |  systemic sclerosis  |  1
C0151744  |  ischaemic heart disease  |  1
C0017661  |  iga nephropathy  |  1
C0011881  |  diabetic nephropathy  |  1
C0376545  |  hematological malignancies  |  1
C0027947  |  neutropenia  |  1
C0271650  |  glucose intolerance  |  1
C0010068  |  coronary heart disease  |  1
C0022661  |  chronic kidney failure  |  1
C0264716  |  chronic heart failure  |  1
C0376545  |  hematologic malignancies  |  1
C0027726  |  nephrotic syndrome  |  1
C0039730  |  thalassemia  |  1
C0029463  |  osteosarcoma  |  1
C1619734  |  pulmonary arterial hypertension  |  1
C0020538  |  hypertensive disease  |  1
C0003864  |  inflammatory arthritis  |  1
C0002871  |  anemia  |  1
C0029434  |  osteogenesis imperfecta  |  1
C0022661  |  chronic renal disease  |  1
C0023418  |  leukemia  |  1
C0020459  |  hyperinsulinaemia  |  1
C0159069  |  impaired glucose tolerance  |  1
Curated Gene
Entrez_id | Symbol | Resource(Total Genes:4)
56606  |  SLC2A9  |  CTD_human
3251  |  HPRT1  |  CTD_human
160728  |  SLC5A8  |  CTD_human
126133  |  ALDH16A1  |  CTD_human
Inferring Gene
Entrez_id | Symbol | Resource(Total Genes:11)
155  |  ADRB3  |  CIPHER
335  |  APOA1  |  CIPHER
337  |  APOA4  |  CIPHER
345  |  APOC3  |  CIPHER
2784  |  GNB3  |  CIPHER
4524  |  MTHFR  |  CIPHER
116085  |  SLC22A12  |  CIPHER
56606  |  SLC2A9  |  CIPHER;CTD_human
3251  |  HPRT1  |  CTD_human
160728  |  SLC5A8  |  CTD_human
126133  |  ALDH16A1  |  CTD_human
Text Mined Gene
Entrez_id | Symbol | Score | Resource(Total Genes:109)
10257  |  ABCC4  |  2.162  |  DISEASES
9619  |  ABCG1  |  1.054  |  DISEASES
55811  |  ADCY10  |  1.925  |  DISEASES
131  |  ADH7  |  1.082  |  DISEASES
9370  |  ADIPOQ  |  1.998  |  DISEASES
135  |  ADORA2A  |  1.035  |  DISEASES
155  |  ADRB3  |  2.273  |  DISEASES
159  |  ADSS  |  1.383  |  DISEASES
229  |  ALDOB  |  3.091  |  DISEASES
344  |  APOC2  |  1.97  |  DISEASES
353  |  APRT  |  1.691  |  DISEASES
9912  |  ARHGAP44  |  2.153  |  DISEASES
23130  |  ATG2A  |  2.874  |  DISEASES
1822  |  ATN1  |  1.32  |  DISEASES
567  |  B2M  |  2.472  |  DISEASES
54828  |  BCAS3  |  1.806  |  DISEASES
834  |  CASP1  |  2.197  |  DISEASES
54897  |  CASZ1  |  1.261  |  DISEASES
8760  |  CDS2  |  2.511  |  DISEASES
1192  |  CLIC1  |  1.671  |  DISEASES
22796  |  COG2  |  2.596  |  DISEASES
85301  |  COL27A1  |  1.636  |  DISEASES
1471  |  CST3  |  2.106  |  DISEASES
1854  |  DUT  |  1.202  |  DISEASES
1892  |  ECHS1  |  1.265  |  DISEASES
1906  |  EDN1  |  2.212  |  DISEASES
2203  |  FBP1  |  1.282  |  DISEASES
51725  |  FBXO40  |  1.055  |  DISEASES
2641  |  GCG  |  1.781  |  DISEASES
2673  |  GFPT1  |  1.094  |  DISEASES
728441  |  GGT2  |  1.898  |  DISEASES
2701  |  GJA4  |  2.312  |  DISEASES
23131  |  GPATCH8  |  3.39  |  DISEASES
2996  |  GYPE  |  1.445  |  DISEASES
3055  |  HCK  |  1.665  |  DISEASES
3174  |  HNF4G  |  3.132  |  DISEASES
3309  |  HSPA5  |  1.111  |  DISEASES
3645  |  INSRR  |  1.795  |  DISEASES
11127  |  KIF3A  |  1.105  |  DISEASES
3965  |  LGALS9  |  1.555  |  DISEASES
4018  |  LPA  |  1.534  |  DISEASES
8972  |  MGAM  |  1.662  |  DISEASES
10724  |  MGEA5  |  2.126  |  DISEASES
326625  |  MMAB  |  1.322  |  DISEASES
51660  |  MPC1  |  1.272  |  DISEASES
4439  |  MSH5  |  1.251  |  DISEASES
4524  |  MTHFR  |  1.66  |  DISEASES
4536  |  MT-ND2  |  1.58  |  DISEASES
4582  |  MUC1  |  2.688  |  DISEASES
4774  |  NFIA  |  1.31  |  DISEASES
22861  |  NLRP1  |  1.506  |  DISEASES
114548  |  NLRP3  |  3.742  |  DISEASES
27031  |  NPHP3  |  1.254  |  DISEASES
261734  |  NPHP4  |  1.947  |  DISEASES
51667  |  NUB1  |  1.635  |  DISEASES
170392  |  OIT3  |  2.831  |  DISEASES
5027  |  P2RX7  |  1.013  |  DISEASES
55742  |  PARVA  |  1.206  |  DISEASES
5174  |  PDZK1  |  3.126  |  DISEASES
5213  |  PFKM  |  3.43  |  DISEASES
5214  |  PFKP  |  1.18  |  DISEASES
57449  |  PLEKHG5  |  1.376  |  DISEASES
4860  |  PNP  |  1.123  |  DISEASES
5631  |  PRPS1  |  3.563  |  DISEASES
221823  |  PRPS1L1  |  3.809  |  DISEASES
5634  |  PRPS2  |  1.439  |  DISEASES
5635  |  PRPSAP1  |  3.904  |  DISEASES
5991  |  RFX3  |  2.955  |  DISEASES
54938  |  SARS2  |  2.42  |  DISEASES
9814  |  SFI1  |  2.421  |  DISEASES
220963  |  SLC16A9  |  3.413  |  DISEASES
10786  |  SLC17A3  |  4.437  |  DISEASES
10050  |  SLC17A4  |  2.686  |  DISEASES
6580  |  SLC22A1  |  1.696  |  DISEASES
387775  |  SLC22A10  |  2.792  |  DISEASES
116085  |  SLC22A12  |  6.679  |  DISEASES
9356  |  SLC22A6  |  5.215  |  DISEASES
10864  |  SLC22A7  |  2.044  |  DISEASES
9376  |  SLC22A8  |  4.514  |  DISEASES
1811  |  SLC26A3  |  1.282  |  DISEASES
65010  |  SLC26A6  |  1.195  |  DISEASES
64078  |  SLC28A3  |  1.196  |  DISEASES
6518  |  SLC2A5  |  3.226  |  DISEASES
159963  |  SLC5A12  |  3.541  |  DISEASES
160728  |  SLC5A8  |  2.982  |  DISEASES
53919  |  SLCO1C1  |  1.246  |  DISEASES
26050  |  SLITRK5  |  2.116  |  DISEASES
4184  |  SMCP  |  1.372  |  DISEASES
94161  |  SNORD46  |  1.471  |  DISEASES
26796  |  SNORD53  |  2.634  |  DISEASES
26774  |  SNORD80  |  2.033  |  DISEASES
9021  |  SOCS3  |  1.427  |  DISEASES
79582  |  SPAG16  |  1.769  |  DISEASES
6696  |  SPP1  |  1.138  |  DISEASES
6708  |  SPTA1  |  2.12  |  DISEASES
9754  |  STARD8  |  1.829  |  DISEASES
7099  |  TLR4  |  1.678  |  DISEASES
7124  |  TNF  |  1.792  |  DISEASES
10345  |  TRDN  |  1.071  |  DISEASES
80128  |  TRIM46  |  1.823  |  DISEASES
10628  |  TXNIP  |  1.03  |  DISEASES
10477  |  UBE2E3  |  2.209  |  DISEASES
29914  |  UBIAD1  |  1.235  |  DISEASES
7498  |  XDH  |  4.772  |  DISEASES
51067  |  YARS2  |  1.444  |  DISEASES
79693  |  YRDC  |  2.144  |  DISEASES
22891  |  ZNF365  |  1.524  |  DISEASES
55663  |  ZNF446  |  3.016  |  DISEASES
124626  |  ZPBP2  |  1.881  |  DISEASES
Locus(Waiting for update.)
Disease ID 750
Disease hyperuricemia
Integrated Phenotype(Waiting for update.)
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:49)
HP:0001997  |  Gout  |  40
HP:0000822  |  Hypertension  |  39
HP:0012622  |  Chronic kidney disease  |  13
HP:0001513  |  Obesity  |  11
HP:0002664  |  Neoplasia  |  10
HP:0000819  |  Diabetes mellitus  |  6
HP:0000855  |  Insulin resistance  |  6
HP:0000083  |  Renal insufficiency  |  5
HP:0012592  |  Albuminuria  |  5
HP:0001635  |  Congestive heart failure  |  5
HP:0000112  |  Nephropathy  |  4
HP:0001397  |  Hepatic steatosis  |  4
HP:0001369  |  Arthritis  |  4
HP:0001919  |  Acute renal failure  |  4
HP:0001677  |  Coronary artery disease  |  4
HP:0002621  |  Atherosclerosis  |  4
HP:0000842  |  Elevated insulin level  |  3
HP:0000833  |  Glucose intolerance  |  3
HP:0003201  |  Rhabdomyolysis  |  2
HP:0000093  |  Proteinuria  |  2
HP:0002665  |  Lymphoma  |  2
HP:0005575  |  Hemolytic-uremic syndrome  |  2
HP:0002155  |  Increased triglycerides  |  2
HP:0000787  |  Renal calculi  |  2
HP:0100602  |  Pre-eclampsia  |  2
HP:0000092  |  Tubular atrophy  |  2
HP:0100601  |  Eclampsia  |  2
HP:0012531  |  Pain  |  2
HP:0001712  |  Left ventricular hypertrophy  |  1
HP:0000752  |  Hyperactive behavior  |  1
HP:0003149  |  High urine uric acid level  |  1
HP:0001941  |  acidemia  |  1
HP:0000100  |  Nephrosis  |  1
HP:0001297  |  Cerebral vascular events  |  1
HP:0002669  |  Osteosarcoma  |  1
HP:0001952  |  Abnormal glucose tolerance  |  1
HP:0001717  |  Coronary artery calcification  |  1
HP:0001714  |  Ventricular hypertrophy  |  1
HP:0010535  |  Sleep apnea  |  1
HP:0001928  |  Abnormal blood coagulation studies  |  1
HP:0012211  |  Renal functional abnormality  |  1
HP:0002104  |  Absence of spontaneous respiration  |  1
HP:0000123  |  Nephritis  |  1
HP:0001909  |  Leukemia  |  1
HP:0001875  |  Neutropenia  |  1
HP:0004950  |  Peripheral artery disease  |  1
HP:0001510  |  Growth deficiency  |  1
HP:0001903  |  Anemia  |  1
HP:0030892  |  DWMH  |  1
Disease ID 750
Disease hyperuricemia
Manually Symptom
UMLS  | Name(Total Manually Symptoms:22)
C2062908  |  acute gout
C1963154  |  renal failure
C1963138  |  hypertension
C1565662  |  acute renal insufficiency
C1565489  |  renal insufficiency
C0948265  |  metabolic syndrome
C0748052  |  erythrodermic psoriasis
C0595916  |  renal toxicity
C0554309  |  azotemia
C0451641  |  urolithiasis
C0403719  |  urate nephropathy
C0403443  |  familial nephropathy
C0341697  |  renal impairment
C0238446  |  tuberculous tenosynovitis
C0028961  |  oliguria
C0025517  |  metabolic disorders
C0022660  |  acute renal failure
C0022658  |  renal disease
C0022658  |  nephropathy
C0022658  |  kidney diseases
C0020473  |  hyperlipidemia
C0011849  |  diabetes mellitus
Text Mined Symptom
UMLS | Name | Sentences' Count(Total Symptoms:11)
C0020538  |  hypertension  |  34
C0948265  |  metabolic syndrome  |  19
C0022658  |  renal disease  |  6
C0011849  |  diabetes mellitus  |  4
C0341697  |  renal impairment  |  3
C0022658  |  nephropathy  |  3
C0025517  |  metabolic disorders  |  3
C0035078  |  renal failure  |  3
C1565489  |  renal insufficiency  |  2
C0451641  |  urolithiasis  |  1
C0403719  |  urate nephropathy  |  1
Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)
Text Mining Genotype(Total Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:27)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs1137070199158684128MAOAumls:C0740394BeFreeWe also found that MAOA enzyme activity by rs1137070 allele was associated with hyperuricemia and gout (P for trend = 1.53 x 10(-6) vs. wild-type allele).0.0002714422010MAOAX43744144TC
rs12218227682676288SAA1umls:C0740394BeFreeThe rs12218 SNP in the SAA1 gene was associated with SUA levels in Chinese subjects, indicating that carriers of the T allele of rs12218 have a high risk of hyperuricemia.0.0002714422012SAA11118269774TC
rs16874954147093727941PLA2G7umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0002714422004NANANANANA
rs16874954147093721666DECR1umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0008143262004NANANANANA
rs1687495414709372345APOC3umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0029099162004NANANANANA
rs16874954147093721535CYBAumls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0008143262004NANANANANA
rs18966005021594610124626ZPBP2umls:C0740394BeFreeZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.0.0002714422011ZPBP21739870781CT
rs223114223238572116085SLC22A12umls:C0740394BeFreeThe strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)).0.0116396632013ABCG2488131171GT
rs2231142234935539429ABCG2umls:C0740394BeFreeThe multidrug ATP-binding cassette, subfamily G, 2 (ABCG2) transporter was recently identified as an important human urate transporter, and a common mutation, a Gln to Lys substitution at position 141 (Q141K), was shown to cause hyperuricemia and gout.0.0138111982013ABCG2488131171GT
rs2231142204212159429ABCG2umls:C0740394GAD[The association of the causal ABCG2 rs2231142 variant with uric acid levels and gout was confirmed in a sample of Japanese ancestry. Our study emphasizes the importance of this common causal variant in a population with a high risk allele frequency, espec]0.0138111982010ABCG2488131171GT
rs2231142232385729429ABCG2umls:C0740394BeFreeThe strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)).0.0138111982013ABCG2488131171GT
rs386594564147093727941PLA2G7umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0002714422004NANANANANA
rs386594564147093721535CYBAumls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0008143262004NANANANANA
rs386594564147093721666DECR1umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0008143262004NANANANANA
rs38659456414709372345APOC3umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0029099162004NANANANANA
rs4673147093721666DECR1umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0008143262004CYBA1688646828AG
rs4673147093727941PLA2G7umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0002714422004CYBA1688646828AG
rs4673147093721535CYBAumls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0008143262004CYBA1688646828AG
rs467314709372345APOC3umls:C0740394BeFreeMultivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.0.0029099162004CYBA1688646828AG
rs499423729572155ADRB3umls:C0740394BeFreeTrp64Arg (rs4994) polymorphism of β3-adrenergic receptor gene is associated with hyperuricemia in a Chinese male population.0.0034527992013ADRB3837966280AG
rs499420008926155ADRB3umls:C0740394BeFreeTrp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain.0.0034527992010ADRB3837966280AG
rs499417225053155ADRB3umls:C0740394BeFreeThe association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor.0.0034527992007ADRB3837966280AG
rs499421285172155ADRB3umls:C0740394BeFreeThe common polymorphism rs4994 [c. T387C, p. Trp64Arg (W64R)] of the lipolysis regulator beta-3-adrenergic receptor (ADRB3) was identified as a marker in the pathogenesis of hyperuricemia.0.0034527992011ADRB3837966280AG
rs505802232385729429ABCG2umls:C0740394BeFreeThe strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)).0.0138111982013SLC22A121164589600TC
rs50580223238572116085SLC22A12umls:C0740394BeFreeThe strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)).0.0116396632013SLC22A121164589600TC
rs5443167078572784GNB3umls:C0740394BeFreeThe C825T variant of the G-protein beta3 subunit (GNB3) gene has attracted renewed attention as a candidate gene for obesity, hypertension and hyperuricemia.0.0026384742006GNB3;CDCA3126845711CT
rs68559112097259556606SLC2A9umls:C0740394BeFreeThe polymorphism rs6855911 in SLC2A9 may be a genetic marker to assess risk of hyperuricemia among Chinese male Han population.0.1287297472011SLC2A949934286AG
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:0)
(Waiting for update.)
Mapped by homologous gene(Total Items:0)
(Waiting for update.)
Disease ID 750
Disease hyperuricemia
Case(Waiting for update.)